Why does this failure matter?

Heart disease remains one of the biggest targets in drug development. Any new medicine that could meaningfully reduce cardiovascular risk would address an enormous medical need, which is why pharmaceutical companies continue to invest heavily in this field despite the high failure rates.

For AstraZeneca, cardiovascular research is a cornerstone of its business strategy. The company has built a portfolio of heart and kidney medicines and has pursued new treatment options through partnerships such as the one with Ionis.

For Ionis, the setback affects an alliance with one of the world's largest pharmaceutical companies. Partnerships like this provide smaller biotech firms with funding, development expertise and commercial reach in exchange for access to their experimental technologies.

What comes next?

The immediate question is what the companies decide to do with the failed program. After a major trial miss, drugmakers typically review the full data set before announcing whether they will stop development entirely, pursue a different patient population, or explore whether any subgroup of patients benefited.

Researchers and investors will also watch for details the companies release about why the drug fell short. Understanding the mechanism behind a failure — whether the drug did not reach its target effectively, or whether the biological hypothesis itself was flawed — helps shape future research in the field.

Patients should not expect the medicine to become available based on this study. Failed trials rarely lead to regulatory filings unless later evidence contradicts the initial result, which is uncommon.

How common are failures like this?

Very common. Cardiovascular drug development carries some of the highest failure rates in the industry because outcomes trials are long, expensive and must show that a new medicine works on top of existing standard treatments such as statins and blood pressure drugs, which already lower risk substantially.

Each high-profile failure, however painful for the companies involved, adds to the scientific record. Other researchers use these results to refine hypotheses about heart disease biology and to design better trials going forward.